Alz Res Therapy: Alzheimer's treatment, artificial intelligence helps "old medicine new use"

Alzheimer's disease (AD) is a chronic neurodegenerative disease associated with progressive cognitive decline, extracellular amyloid plaques, intracellular neurofibrillary tangles, and neuronal death

In fact, the U.

The number of AD patients is projected to rise to 13.

To address this key issue in the field, they developed a web-based artificial intelligence framework capable of integrating multi-omics data as well as human protein-protein interactome networks to accurately infer GWAS-confirmed variants affected by Accurate drug targets to identify new treatments

Using this approach, they identified 103 AD ARGs that were validated by varying degrees of pathobiological evidence

In a retrospective case-control validation, pioglitazone use was significantly associated with a reduction in AD risk (hazard ratio (HR) = 0.

Pioglitazone, a peroxisome proliferator-activated receptor (PPAR) agonist for the treatment of type 2 diabetes , was demonstrated in a propensity-score-matched cohort study to be comparable to glipizide (HR = 0.

In vitro experiments showed that pioglitazone down-regulated glycogen synthase 3β (GSK3β) and cyclin-dependent kinase (CDK5) in human microglia, supporting a possible mechanism of action for its beneficial effects on AD